

**Reference:** FOI.ICB-2223/063

**Subject:** BNSSG Formulary

*I can confirm that the ICB **does hold the information requested**; please see responses below:*

QUESTION	RESPONSE
<p>I am requesting the following information in respect of:</p> <ul style="list-style-type: none"> <li>• Diabetes (SMBG test strips/pen needles)</li> <li>• Wound Care</li> <li>• Urology</li> <li>• Oral contraceptives</li> </ul> <p>For each area:</p> <ol style="list-style-type: none"> <li>1. The name(s) and direct contact email address(es) and direct telephone numbers of the person(s) in your Medicines Management team/ICB/Health Board who are responsible for the formulary</li> <li>2. The date of the next review of your formulary</li> <li>3. Details of how you intend to review your formulary (include process, timelines)</li> </ol>	<ol style="list-style-type: none"> <li>1. The following roles in Bristol, North Somerset and South Gloucestershire Integrated Care Board (BNSSG ICB) Medicines Optimisation Team are responsible for supporting the BNSSG Joint Formulary in the 4 areas listed in this FOI: <ul style="list-style-type: none"> <li>• Interface Pharmacist, NHS BNSSG ICB</li> <li>• Senior Medicines Optimisation Pharmacist, NHS BNSSG ICB</li> <li>• Senior Medicines Optimisation Pharmacist - Diabetes Lead</li> <li>• Medicines Optimisation Senior Pharmacy Technician, NHS BNSSG ICB</li> <li>• Principal Pharmacist, Medicines Optimisation, NHS BNSSG ICB</li> <li>• GP Prescribing Lead, NHS BNSSG ICB</li> <li>• Deputy Director, Medicines Optimisation, NHS BNSSG ICB</li> </ul> </li> </ol> <p>Email: <a href="mailto:Bnssg.medicines-optimisation@nhs.net">Bnssg.medicines-optimisation@nhs.net</a> Phone: <a href="tel:01179766600">0117 976 6600</a></p>

4. Details of ICB/Health Board if part of a local partnership arrangement for formulary review. Please provide the contact's name, email address and telephone number for the person with responsibility where a partnership arrangement is in place.

2. BNSSG Joint Formulary Group meetings are held approximately every 6 weeks. The next meeting is on Tuesday 1<sup>st</sup> November 2022.

3. Where new drug applications are considered within the BNSSG Joint Formulary Group the relevant section of the formulary is considered within the context of the formulary application and this may result in a review of that section. We also have a rolling timetable for reviewing each chapter within the BNSSG Joint Formulary so that each chapter is expected to be reviewed every 2 years. The schedule of this has been delayed due to the pressure of the COVID-19 pandemic. Our usual process is to establish a working group for each chapter review that involves representation from the relevant specialist teams, community and primary care across BNSSG to input into the chapter update. Guidelines within the BNSSG Joint Formulary are expected to be reviewed every 2 years or sooner if national policy or evidence changes.

4. The BNSSG Joint Formulary Group is an established group comprising of representation from all sectors of the Integrated Care System to include primary care, secondary care, community services, mental health and local authority.

This group is co-ordinated and managed by the following ICB roles:

- Interface Pharmacist, NHS BNSSG ICB



**Bristol, North Somerset  
and South Gloucestershire**

**Integrated Care Board**

- |  |   |
|--|---|
|  | <ul style="list-style-type: none"><li>• Principal Pharmacist, Medicines Optimisation, NHS BNSSG ICB</li><li>• GP Prescribing Lead, NHS BNSSG ICB</li><li>• Deputy Director, Medicines Optimisation, NHS BNSSG ICB</li></ul> |
|--|---|

Email: [Bnssg.medicines-optimisation@nhs.net](mailto:Bnssg.medicines-optimisation@nhs.net)

Phone: [0117 976 6600](tel:0117 976 6600)

***The information provided in this response is accurate as of 22 September 2022 and has been approved for release by Dr Joanne Medhurst, Chief Medical Officer Designate for NHS Bristol, North Somerset and South Gloucestershire ICB.***